A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies (NCT05338346)
ATRIUM
This trial is No longer recruiting
Registration number NCT05338346
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Malaka Ameratunga
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR